Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$204.93 -0.6%	$199.66	$153.58 ▼ $218.66	$362.52B	0.61	5.74 million shs	9.25 million shs
ABT Abbott Laboratories	$132.10 +0.3%	$131.03	$99.71 ▼ $141.23	$229.10B	0.7	5.85 million shs	4.23 million shs
AMGN Amgen	$305.70 -0.4%	$303.16	$253.30 ▼ $346.85	$164.22B	0.53	2.70 million shs	1.91 million shs
PFE Pfizer	$24.73 +0.8%	$25.98	$24.31 ▼ $31.54	$140.26B	0.61	39.09 million shs	41.78 million shs
REGN Regeneron Pharmaceuticals	$625.60 +1.4%	$680.43	$605.56 ▼ $1,211.20	$68.39B	0.27	676,916 shs	899,886 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.56%	+1.87%	-3.00%	+14.21%	+13.40%
ABT Abbott Laboratories	+0.30%	+4.46%	-5.73%	+16.45%	+17.93%
AMGN Amgen	-0.40%	0.00%	-1.63%	+17.90%	+10.68%
PFE Pfizer	+0.84%	-1.84%	-5.65%	-7.07%	-10.24%
REGN Regeneron Pharmaceuticals	+1.39%	-2.27%	-8.65%	-12.53%	-34.47%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.5381 of 5 stars	2.5	3.0	3.3	3.9	3.4	2.5	1.3
ABT Abbott Laboratories	4.9016 of 5 stars	2.4	4.0	4.2	4.5	3.5	2.5	2.5
AMGN Amgen	4.4467 of 5 stars	2.2	4.0	3.3	3.9	3.6	2.5	0.6
PFE Pfizer	4.9865 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
REGN Regeneron Pharmaceuticals	4.8218 of 5 stars	4.4	3.0	1.7	2.3	3.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	3.18% Upside
ABT Abbott Laboratories	2.84	Moderate Buy	$137.94	4.42% Upside
AMGN Amgen	2.48	Hold	$314.04	2.73% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	29.09% Upside
REGN Regeneron Pharmaceuticals	2.76	Moderate Buy	$966.88	54.55% Upside

Current Analyst Ratings Breakdown

Latest ABT, ABBV, AMGN, PFE, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$1,100.00 ➝ $1,000.00
3/27/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/17/2025	ABBV AbbVie	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	ABT Abbott Laboratories	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$133.00 ➝ $150.00
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/5/2025	AMGN Amgen	Johnson Rice Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$294.00
3/5/2025	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $240.00
3/5/2025	AMGN Amgen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$275.00 ➝ $294.00
3/4/2025	ABBV AbbVie	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$200.00 ➝ $223.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.44	$15.15 per share	13.53	$1.90 per share	107.86
ABT Abbott Laboratories	$41.95B	5.46	$5.69 per share	23.22	$22.36 per share	5.91
AMGN Amgen	$33.42B	4.91	$30.63 per share	9.98	$10.93 per share	27.97
PFE Pfizer	$63.63B	2.20	$3.88 per share	6.38	$15.81 per share	1.56
REGN Regeneron Pharmaceuticals	$14.20B	4.82	$41.08 per share	15.23	$268.50 per share	2.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	85.39	14.66	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
ABT Abbott Laboratories	$13.40B	$7.65	17.27	23.05	2.52	31.95%	20.74%	11.19%	4/16/2025 (Estimated)
AMGN Amgen	$4.09B	$7.55	40.49	14.29	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.54	8.16	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$38.28	16.34	16.45	2.34	31.07%	16.32%	12.76%	4/29/2025 (Estimated)

Latest ABT, ABBV, AMGN, PFE, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	AMGN Amgen	$4.18	N/A	N/A	N/A	$8.05 billion	N/A
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/29/2025	N/A	REGN Regeneron Pharmaceuticals	$8.83	N/A	N/A	N/A	$3.40 billion	N/A
4/25/2025	N/A	ABBV AbbVie	$2.51	N/A	N/A	N/A	$12.91 billion	N/A
4/16/2025	N/A	ABT Abbott Laboratories	$1.07	N/A	N/A	N/A	$10.38 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
2/4/2025	Q4 24	REGN Regeneron Pharmaceuticals	$11.21	$12.07	+$0.86	$8.06	$3.76 billion	$3.79 billion
1/31/2025	Q4 24	ABBV AbbVie	$2.98	$2.16	-$0.82	-$0.02	$14.81 billion	N/A
1/22/2025	Q4 2024	ABT Abbott Laboratories	$1.34	$1.34	N/A	$5.27	$11.03 billion	$10.97 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.20%	+6.04%	273.33%	53 Years
ABT Abbott Laboratories	$2.36	1.79%	+7.17%	30.85%	54 Years
AMGN Amgen	$9.52	3.11%	+8.53%	126.09%	14 Years
PFE Pfizer	$1.72	6.96%	+2.50%	121.99%	16 Years
REGN Regeneron Pharmaceuticals	$0.88	0.14%	N/A	2.30%	N/A

Latest ABT, ABBV, AMGN, PFE, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
2/21/2025	ABT Abbott Laboratories	quarterly	$0.59	1.75%	4/15/2025	4/15/2025	5/15/2025
2/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.53%	2/20/2025	2/20/2025	3/20/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
ABT Abbott Laboratories	0.32	1.60	1.14
AMGN Amgen	9.62	1.26	0.95
PFE Pfizer	0.63	1.00	0.73
REGN Regeneron Pharmaceuticals	0.09	4.73	3.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
AMGN Amgen	76.50%
PFE Pfizer	68.36%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
ABT Abbott Laboratories	0.46%
AMGN Amgen	0.69%
PFE Pfizer	0.06%
REGN Regeneron Pharmaceuticals	7.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
ABT Abbott Laboratories	115,000	1.73 billion	1.73 billion	Optionable
AMGN Amgen	28,000	537.21 million	533.50 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
REGN Regeneron Pharmaceuticals	11,900	109.33 million	101.15 million	Optionable

ABT, ABBV, AMGN, PFE, and REGN Headlines

Recent News About These Companies

Geode Capital Management LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 3 at 5:55 AM | marketbeat.com

Gilead, Regeneron have most theoretical PDUFA date risk, says BofA

April 3 at 4:17 AM | markets.businessinsider.com

Is Regeneron Pharmaceuticals, Inc. (REGN) The Most Profitable Biotech Stock To Buy Right Now?

April 2 at 10:30 AM | insidermonkey.com

Groupama Asset Managment Has $56.45 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 7:06 AM | marketbeat.com

Trexquant Investment LP Acquires 42,674 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 6:46 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Alliancebernstein L.P.

April 2 at 5:33 AM | marketbeat.com

Schroder Investment Management Group Sells 13,477 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 4:49 AM | marketbeat.com

WINTON GROUP Ltd Sells 755 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 2 at 4:07 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low on Analyst Downgrade

April 1 at 11:12 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,000.00 at JPMorgan Chase & Co.

April 1 at 10:56 AM | marketbeat.com

RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO

April 1 at 10:02 AM | youtube.com

Franklin Resources Inc. Has $1.46 Billion Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 7:09 AM | marketbeat.com

Cannell & Spears LLC Has $11.44 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:49 AM | marketbeat.com

Summit Financial LLC Has $7.50 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:39 AM | marketbeat.com

AIA Group Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

April 1 at 6:01 AM | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,000.00 by Analysts at JPMorgan Chase & Co.

April 1 at 2:39 AM | americanbankingnews.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low After Analyst Downgrade

April 1 at 1:23 AM | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (REGN): Among Blue Chip Stocks to Invest in at 52-Week Lows

March 31 at 8:23 PM | finance.yahoo.com

Regeneron price target lowered to $1,000 from $1,100 at JPMorgan

March 31 at 5:55 PM | markets.businessinsider.com

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

March 31 at 10:10 AM | zacks.com

California Public Employees Retirement System Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

March 31 at 6:31 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
By Chris Markoch | March 23, 2025
View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
By Gabriel Osorio-Mazilli | April 1, 2025
View 2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

ABT, ABBV, AMGN, PFE, and REGN Company Descriptions

AbbVie NYSE:ABBV

$204.93 -1.34 (-0.65%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$207.06 +2.13 (+1.04%)

As of 08:03 AM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$132.10 +0.41 (+0.31%)

Closing price 04/2/2025 03:58 PM Eastern

Extended Trading

$130.70 -1.41 (-1.06%)

As of 08:03 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$305.70 -1.22 (-0.40%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$309.17 +3.47 (+1.14%)

As of 08:04 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Pfizer NYSE:PFE

$24.73 +0.19 (+0.77%)

Closing price 04/2/2025 03:59 PM Eastern

Extended Trading

$24.62 -0.11 (-0.42%)

As of 08:04 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals NASDAQ:REGN

$625.60 +8.60 (+1.39%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$611.30 -14.30 (-2.29%)

As of 08:03 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABT, ABBV, AMGN, PFE, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABT, ABBV, AMGN, PFE, and REGN Earnings

Compare Dividends

Latest ABT, ABBV, AMGN, PFE, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABT, ABBV, AMGN, PFE, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABT, ABBV, AMGN, PFE, and REGN Company Descriptions

AbbVie NYSE:ABBV

Abbott Laboratories NYSE:ABT

Amgen NASDAQ:AMGN

Pfizer NYSE:PFE

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools